Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? A retrospective cohort study.
Adult
Cause of Death
Cohort Studies
Drug Overdose
/ mortality
Female
Humans
Ireland
Male
Methadone
/ therapeutic use
Middle Aged
Narcotics
/ therapeutic use
Opiate Substitution Treatment
/ mortality
Opioid-Related Disorders
/ drug therapy
Patient Transfer
/ statistics & numerical data
Retrospective Studies
Risk Factors
All-cause mortality
drug-related poisoning mortality
heroin
methadone maintenance treatment
opioid substitution treatment
opioid-use disorder
transfer
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
23
09
2019
revised:
02
12
2019
accepted:
05
02
2020
pubmed:
9
2
2020
medline:
20
4
2021
entrez:
9
2
2020
Statut:
ppublish
Résumé
To examine the risk of mortality associated with interruptions to the continuity of methadone maintenance treatment (MMT), including transfers between services, in opioid-dependent individuals attending specialist addiction services. Retrospective cohort study using addiction services and primary care dispensing records, the National Methadone Register and National Drug-Related Death Index (NDRDI). Geographically defined population in Dublin, Ireland. A total of 2899 people prescribed and dispensed methadone in specialist addiction services between January 2010 and December 2015. There were five exposure groups: weeks 1-4 following transfer between treatment providers; weeks 1-4 out of treatment; weeks 5-52 out of treatment; weeks 1-4 of treatment initiation; and weeks 5+ of continuous treatment (reference category). Primary outcome: drug-related poisoning (DRP) deaths. Secondary outcome: all-cause mortality (ACM). Mortality rates calculated by dividing number of deaths (DRP; ACM) in exposure groups by person-years exposure. Unadjusted and adjusted Poisson regression (covariates age, sex, incarceration, methadone dose and comorbidities) estimated differences in mortality rates. There were 154 ACM deaths, 55 (35.7%) identified as DRP deaths. No deaths were observed in the first month following transfer between treatment providers. The risk of DRP mortality was highest in weeks 1-4 out of treatment [adjusted relative risk (aRR = 4.04, 95% confidence interval (CI) = 1.43-11.43, P = 0.009] and weeks 1-4 of treatment initiation (ARR = 3.4, 95% CI = 1.2-9.64, P = 0.02). Similarly, risk of ACM was highest in weeks 1-4 out of treatment (ARR = 11.78, 95% CI = 7.73-17.94, P < 0.001), weeks 1-4 of treatment initiation (aRR = 5.11, 95% CI = 2.95-8.83, P < 0.001) and weeks 5-52 off treatment (aRR = 2.04, 95% CI = 1.2-3.47, P = 0.009). Interruptions to the continuity of methadone maintenance treatment by treatment provider do not appear to be periods of risk for drug-related poisoning or all-cause mortality deaths. Risk of drug related poisoning and all-cause mortality deaths appears to be greatest during the first 4 weeks of treatment initiation/re-initiation and after treatment cessation.
Identifiants
pubmed: 32034837
doi: 10.1111/add.15004
pmc: PMC7540578
doi:
Substances chimiques
Narcotics
0
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1867-1877Informations de copyright
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Addiction. 2015 Jun;110(6):996-1005
pubmed: 25644938
Harm Reduct J. 2019 Jan 17;16(1):5
pubmed: 30654803
Addiction. 2018 Aug;113(8):1461-1476
pubmed: 29672985
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
BMC Fam Pract. 2018 Jun 30;19(1):103
pubmed: 29960593
Lancet Psychiatry. 2015 Oct;2(10):901-8
pubmed: 26384619
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
Addiction. 2018 May;113(5):946-951
pubmed: 29179255
Addiction. 2016 Jan;111(1):73-82
pubmed: 26234389
BMJ. 2018 Nov 14;363:k4524
pubmed: 30429122
Addiction. 2017 Aug;112(8):1408-1418
pubmed: 28160345
Addiction. 2008 Sep;103(9):1484-92
pubmed: 18636999
Addiction. 2009 Jul;104(7):1193-200
pubmed: 19563562
BMJ. 2010 Oct 26;341:c5475
pubmed: 20978062
Addiction. 2010 Sep;105(9):1545-54
pubmed: 20579009
PLoS One. 2015 Oct 23;10(10):e0140995
pubmed: 26495843
BMJ. 2009 Jun 16;338:b2225
pubmed: 19535400
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Br J Clin Pharmacol. 2019 Jan;85(1):202-215
pubmed: 30338545
Addiction. 2007 Dec;102(12):1954-9
pubmed: 18031430
Drug Alcohol Depend. 2006 Jan 4;81(1):55-61
pubmed: 15993552
Addiction. 2002 Aug;97(8):993-1001
pubmed: 12144602
Addiction. 2009 Aug;104(8):1363-72
pubmed: 19549053
BMJ Open. 2018 Apr 13;8(4):e021122
pubmed: 29654048
Drug Alcohol Depend. 2009 Nov 1;105(1-2):9-15
pubmed: 19608355
BMJ. 2010 Jul 01;341:c3172
pubmed: 20595255
Addiction. 2014 Aug;109(8):1306-17
pubmed: 24612249
Addiction. 2020 Oct;115(10):1867-1877
pubmed: 32034837
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Drug Alcohol Depend. 2017 Apr 01;173:126-131
pubmed: 28232249
Clin Infect Dis. 2015 Oct 1;61(7):1157-65
pubmed: 26113656
J Subst Abuse Treat. 2011 Oct;41(3):252-60
pubmed: 21696913
BMJ Open. 2019 Jun 4;9(6):e024747
pubmed: 31167862